Laura Joszt

Since the recession began in 2008, states have been struggling to balance their budgets, which often lead to tax increases.

In the run up to next week's FDA decision on Arena Pharmaceuticals' weight-loss drug, investors have been sending the biotech's stock up.

After five years of audits to discover Medicaid fraud, $102 million were spent to find only $20 million in overpayments.

Regeneron hasn't regained its footing since a rival eye drug combo worked in a trial.

Of the major emerging markets, only China and India have shown an increase over the past few years with the satisfaction of personal health. Russians are the least satisfied.

A vacation can turn into sour very quickly if you discover you've become the victim of identity theft or a scam.

A female physician researcher might find the idea of a $12,194 raise enticing, and she would only have to do one thing: swap genders.

The student loan debt bomb is understandably worrisome, but medical students have less to be concerned about.

Eli Lilly & Co. is taking a shot at Sanofi with a new drug that matches Sanofi's Lantus at controlling blood sugar, but also helps patients lose weight.

Americans working full time or part time had healthier habits than people who were unemployed. And the healthiest group of all was those people not in the workforce.

The Supreme Court will rule on the Affordable Care Act this month, but physicians grade the law so poorly, they think it should be scrapped and that Congress should start over.

In three months, the FDA will rule whether or not to approve Gilead Sciences' Truvada for HIV prevention, giving the company a huge advantage in a market it is already a leader in.

Despite the fact that U.S. health costs are among the highest in the world, its physicians are among the lowest paid of the major western nations (relatively speaking).

A late-stage trial of Amgen's drug Sensipar failed to meet the trial goal causing shares to fall, but only a little.

Summer is the ideal time for road trips. Whether you're just driving to the beach or trekking across the country, here are some money-saving tips.

The strong set of drugs in Spectrum Pharmaceuticals' pipeline could mean that the company has some long-term potential for investors.

Anticoagulants lead in the most number of reports for serious adverse events. In 2011 there was an increase of 9.4% in reported cases.

According to the CEO of AIG, because of longer life expectancies, retirement age might be pushed back to 70 or 80.

Roche has so impressed since ASCO with its various drug results - including its "smart bomb" breast cancer drug trastuzumab emtansine (T-DMI) - that the company's stock (RHHBY) shot up on the OTC Markets.

If you miss out on happiness in your 30s you could have another chance in your 60s, according to an AARP survey.

The most common form of compensation for on-call physicians is a daily stipend, and pay varies depending on specialty, location and group type.

After pipeline disappointments a corporate shake up might be just what Targacept needs as it moves forward with its remaining drugs.

Although Ampio has had a volatile few months, with three strong drugs in the pipeline, the company is positioning itself for a rebound.

While alternative investments have continued to gain assets, excitement for them has diminished, which lead to slower growth in 2011.

The markets opened on Monday with a host of new data from ASCO, including impressive news from Bristol and bad news for Dendreon.

By 2030 the number of people with cancer worldwide could increase by more than 75%.

The roller coaster isn't over for the diabetes drug maker's stock, which first shot up in March over news that Bristol had placed a bid. But is the stock now overweight?

Despite the expectation that health care spending growth would increase in 2012, it has not. In fact, it's also expected to remain slow in 2013.

After a failed midstage trial for a rheumatoid arthritis drug, Chelsea Therapeutics announced it ended studies on the drug causing the company's stock to plummet 33%.

Abbott Laboratories, which has a strong track record for dividend yield growth, is on the edge of something very big as it prepares to split the company into two.